Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer

Elisa Capizzi, Elena Gabusi, Antonia Derrico Grigioni, Pierandrea De Iaco, Marta Rosati, Claudio Zamagni, Michelangelo Fiorentino

Research output: Contribution to journalArticle


OBJECTIVES: A nonrandomized trial was planned to investigate the role of free plasma DNA (FPDNA) in patients with epithelial ovarian cancer before and after chemotherapy. Twenty-two patients with advanced stage ovarian cancer not suitable for debulking were treated with a neoadjuvant platinum/taxanes chemotherapy. Patients with clinical complete or partial response underwent radical hystero-oophorectomy, omentectomy, and lymphadenectomy and were followed up every 3 to 6 months. METHODS: Blood samples were obtained from each patient before chemotherapy, before each cycle, before and after surgery. FPDNA was quantified by real-time quantitative polymerase chain reaction using the Quantifiler Human Quantification Kit and expressed in ng/mL. Fifty female healthy blood donor volunteers were used as controls. RESULTS: Median FPDNA quantities discriminated between patients before chemotherapy (29.6±22.7mL) and controls (6.4±4. /mL) using a 14.5mL cutoff with 77% sensitivity and 96% specificity (P

Original languageEnglish
Pages (from-to)34-38
Number of pages5
JournalDiagnostic Molecular Pathology
Issue number1
Publication statusPublished - Mar 2008



  • CA-125
  • Chemotherapy
  • Epithelial ovarian cancer
  • Free plasma DNA
  • Molecular pathology

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Pathology and Forensic Medicine

Cite this